TW200940709A - Oncolytic viruses as phenotyping agents for neoplasms - Google Patents

Oncolytic viruses as phenotyping agents for neoplasms Download PDF

Info

Publication number
TW200940709A
TW200940709A TW098118162A TW98118162A TW200940709A TW 200940709 A TW200940709 A TW 200940709A TW 098118162 A TW098118162 A TW 098118162A TW 98118162 A TW98118162 A TW 98118162A TW 200940709 A TW200940709 A TW 200940709A
Authority
TW
Taiwan
Prior art keywords
neoplasms
oncolytic viruses
tumors
reovirus
cells
Prior art date
Application number
TW098118162A
Other languages
English (en)
Other versions
TWI402345B (zh
Inventor
Bradley G Thompson
Matthew C Coffey
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of TW200940709A publication Critical patent/TW200940709A/zh
Application granted granted Critical
Publication of TWI402345B publication Critical patent/TWI402345B/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/14—Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW098118162A 2002-06-28 2003-06-26 做為腫瘤表現型分類劑之溶瘤病毒 TWI402345B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39203102P 2002-06-28 2002-06-28
US44318803P 2003-01-29 2003-01-29

Publications (2)

Publication Number Publication Date
TW200940709A true TW200940709A (en) 2009-10-01
TWI402345B TWI402345B (zh) 2013-07-21

Family

ID=30003222

Family Applications (3)

Application Number Title Priority Date Filing Date
TW098118162A TWI402345B (zh) 2002-06-28 2003-06-26 做為腫瘤表現型分類劑之溶瘤病毒
TW098135545A TWI334444B (en) 2002-06-28 2003-06-26 Oncolytic viruses as phenotyping agents for neoplasms
TW092117377A TWI327167B (en) 2002-06-28 2003-06-26 Oncolytic viruses as phenotyping agents for neoplasms

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW098135545A TWI334444B (en) 2002-06-28 2003-06-26 Oncolytic viruses as phenotyping agents for neoplasms
TW092117377A TWI327167B (en) 2002-06-28 2003-06-26 Oncolytic viruses as phenotyping agents for neoplasms

Country Status (20)

Country Link
US (3) US7306902B2 (zh)
EP (2) EP1520175B1 (zh)
JP (1) JP2005531306A (zh)
CN (1) CN1666105B (zh)
AR (1) AR039768A1 (zh)
AT (2) ATE377754T1 (zh)
AU (2) AU2003245760B2 (zh)
BR (1) BR0311983A (zh)
CA (1) CA2487824C (zh)
DE (1) DE60317331T2 (zh)
DK (2) DK1520175T3 (zh)
ES (2) ES2385845T3 (zh)
HK (2) HK1069877A1 (zh)
IL (2) IL165498A0 (zh)
MX (1) MXPA04012414A (zh)
NZ (1) NZ537116A (zh)
PT (1) PT1890151E (zh)
SI (1) SI1890151T1 (zh)
TW (3) TWI402345B (zh)
WO (1) WO2004003562A2 (zh)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
US7306902B2 (en) * 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US20040115170A1 (en) * 2001-11-30 2004-06-17 Brown Earl Garnet Oncolytic virus
WO2004009763A2 (en) 2002-07-24 2004-01-29 Arizona Board Of Regents Use of vaccinia virus deleted for the e3l gene as a vaccine vector
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
EP1648233A4 (en) * 2003-07-08 2006-08-23 Univ Arizona VACCINE VACCINE MUTANTS INSTEAD OF ONCOLYTIC AGENTS
WO2005111200A1 (en) * 2004-05-17 2005-11-24 Universite De Montreal Novel strains of reoviruses and methods of uses thereof
CA2617600A1 (en) 2005-08-01 2007-09-07 University Technologies International, Inc. Attenuated reovirus
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
ATE516370T1 (de) * 2005-12-22 2011-07-15 Sloan Kettering Inst Cancer Verfahren zur erfassung von krebszellen unter verwendung eines virus
US20070190032A1 (en) * 2006-02-13 2007-08-16 Oncolytics Biotech Inc. Use of Local Immune Suppression to Enhance Oncolytic Viral Therapy
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
US9241998B2 (en) * 2007-05-21 2016-01-26 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oncolytic RSV activity
WO2009143468A1 (en) * 2008-05-22 2009-11-26 Uti Limited Partnership Tumor suppressor-based susceptibility of hyperproliferative cells to oncolytic viral therapy
WO2009143611A1 (en) * 2008-05-27 2009-12-03 Oncolytics Biotech Inc. Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
US20110086005A1 (en) * 2008-05-27 2011-04-14 Oncolytics Biotech Inc. Modulating interstitial pressure and oncolytic viral delivery and distribution
WO2010080909A1 (en) * 2009-01-08 2010-07-15 Yale University Compositions and methods of use of an oncolytic vesicular stomatitis virus
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
EP2670426B1 (en) 2011-01-31 2017-05-10 The General Hospital Corporation Multimodal trail molecules and uses in cellular therapies
WO2013052915A2 (en) 2011-10-05 2013-04-11 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
WO2013138522A2 (en) 2012-03-16 2013-09-19 Genelux Corporation Methods for assessing effectiveness and monitoring oncolytic virus treatment
US20130280170A1 (en) 2012-04-20 2013-10-24 Aladar A. Szalay Imaging methods for oncolytic virus therapy
EP3473708B1 (en) 2012-07-24 2021-01-27 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
WO2014035474A1 (en) 2012-08-30 2014-03-06 The General Hospital Corporation Compositions and methods for treating cancer
WO2014055960A1 (en) 2012-10-05 2014-04-10 Genelux Corporation Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes
EP3082834B1 (en) * 2013-12-11 2020-03-11 The General Hospital Corporation DBA Massachusetts Stem cell delivered oncolytic herpes simplex virus and methods for treating brain tumors
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
PL3207130T3 (pl) 2014-10-14 2020-02-28 Halozyme, Inc. Kompozycje deaminazy adenozyny 2 (ada2), jej warianty i sposoby ich zastosowania
CN107735103B (zh) 2015-02-25 2022-05-27 纪念斯隆-凯特琳癌症中心 使用灭活的非复制型的修饰的痘苗病毒安卡拉(mva)作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂的组合
CN116173193A (zh) 2015-04-17 2023-05-30 纪念斯隆凯特琳癌症中心 Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用
IL261321B2 (en) 2016-02-25 2023-12-01 Memorial Sloan Kettering Cancer Center Recombinant MVA or MVADELE3L expressing human FLT3L and their use as immunotherapeutic agents against solid tumors
AU2017222686B2 (en) 2016-02-25 2021-12-23 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
AU2017250358B2 (en) 2016-04-15 2023-06-01 Alpine Immune Sciences, Inc. ICOS ligand variant immunomodulatory proteins and uses thereof
IL310729A (en) 2016-04-15 2024-04-01 Alpine Immune Sciences Inc Immunomodulatory proteins that are variants of CD80 and their uses
WO2017205674A1 (en) 2016-05-25 2017-11-30 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic vaccinia virus mutants and using same for cancer treatment
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
CA3032120A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
MX2019003546A (es) * 2016-09-27 2019-09-19 Sator Therapeutics LLC Virus oncoliticos optimizados y usos de los mismos.
WO2018075978A1 (en) 2016-10-20 2018-04-26 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
CN110546265A (zh) 2017-02-09 2019-12-06 因达普塔治疗公司 工程化自然杀伤(nk)细胞及其组合物和方法
PL3596116T3 (pl) 2017-03-16 2024-05-13 Alpine Immune Sciences, Inc. Białka immunomodulujące wariant Pd-l1 i ich zastosowania
WO2018170023A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Pd-l2 variant immunomodulatory proteins and uses thereof
JP7386083B2 (ja) 2017-03-16 2023-11-24 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｄ８０バリアント免疫調節タンパク質及びその使用
WO2018209315A1 (en) 2017-05-12 2018-11-15 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
CA3078517A1 (en) 2017-10-18 2019-04-25 Alpine Immune Sciences, Inc. Variant icos ligand immunomodulatory proteins and related compositions and methods
CN112533621A (zh) 2018-06-04 2021-03-19 卡利迪生物治疗有限公司 强化病毒疗法的基于细胞的媒介
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
US20210363219A1 (en) 2018-06-15 2021-11-25 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
WO2020047161A2 (en) 2018-08-28 2020-03-05 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
AU2019377141B2 (en) 2018-11-06 2024-06-06 Calidi Biotherapeutics (Nevada), Inc. Enhanced systems for cell-mediated oncolytic viral therapy
KR20210123289A (ko) 2018-11-21 2021-10-13 인답타 세라뷰틱스 인코포레이티드 자연 살해 세포 서브세트의 증식을 위한 방법 및 관련 조성물 및 방법
KR20210135987A (ko) 2018-11-30 2021-11-16 알파인 이뮨 사이언시즈, 인코포레이티드 Cd86 변이체 면역조절 단백질 및 그의 용도
SG11202108459QA (en) 2019-02-27 2021-09-29 Actym Therapeutics Inc Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
AU2021258194A1 (en) 2020-04-22 2022-11-24 Indapta Therapeutics, Inc. Natural killer (NK) cell compositions and methods for generating same
WO2022147480A1 (en) 2020-12-30 2022-07-07 Ansun Biopharma, Inc. Oncolytic virus encoding sialidase and multispecific immune cell engager

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US5670330A (en) * 1992-09-29 1997-09-23 Mcgill University Anti-tumor agent assay using PKR
US5801029A (en) * 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
DK0931830T3 (da) 1993-02-16 2001-06-11 Onyx Pharma Inc Cytopatiske vira til terapi og profylakse af neoplasi
DE69432409T2 (de) 1993-04-30 2003-12-24 Wellstat Biologics Corp Verwendung der NDV zur Herstellung eines Medikaments zur Krebsbehandlung
JPH09506866A (ja) * 1993-12-14 1997-07-08 ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 医薬として活性のある物質の免疫療法のための放出制御
WO1995032300A1 (en) * 1994-05-23 1995-11-30 University Of Medicine & Dentistry Of New Jersey Selective biological destruction of tumor cells
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5840502A (en) * 1994-08-31 1998-11-24 Activated Cell Therapy, Inc. Methods for enriching specific cell-types by density gradient centrifugation
US6777177B1 (en) * 1997-10-10 2004-08-17 Vanderbilt University Mammalian genes involved in viral infection and tumor suppression
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
CA2508238C (en) 1997-08-13 2008-01-15 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
ES2292207T3 (es) * 1997-10-09 2008-03-01 Wellstat Biologics Corporation Tratamiento de neoplasmas con virus clonales, sensibles al interferon.
US6475481B2 (en) * 1997-11-18 2002-11-05 Canji Inc Purging of stem cell products
EP1061806A4 (en) 1998-03-12 2001-09-12 Univ Pennsylvania PRODUCTIVE CELLS FOR REPLICATION-SELECTIVE VIRUSES FOR TREATING Vicious DISEASES
WO2000012103A1 (en) * 1998-08-31 2000-03-09 Ambrus Julian L Method for removal of hiv and other viruses from blood
JP2003530301A (ja) 1999-04-15 2003-10-14 ウェルスタット バイオロジクス コーポレイション ウイルスを用いた新生物の処置
DE19934788B4 (de) * 1999-07-27 2004-05-27 T-Mobile Deutschland Gmbh Verfahren zur automatischen Anpassung von Daten an die Fähigkeiten einer Nutzer-Software
WO2001019380A2 (en) 1999-09-17 2001-03-22 Pro-Virus, Inc. Oncolytic virus
EP1227828A1 (en) * 1999-11-12 2002-08-07 Oncolytics Biotech, Inc. Viruses for the treatment of cellular proliferative disorders
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US7306902B2 (en) * 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
AR028040A1 (es) 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de virus de celulas neoplasticas a partir de composiciones celulares mixtas
AR028039A1 (es) * 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
ATE294858T1 (de) * 2000-06-26 2005-05-15 Wellstat Biologics Corp Entfernung von zellen mit viren
WO2002004596A2 (en) 2000-07-07 2002-01-17 President And Fellows Of Harvard College Diagnosing and treating cancer cells using mutant viruses
DK1332366T3 (da) 2000-11-09 2010-08-02 Oncolytics Biotech Inc Fremgangsmåde til vurdering af cellulære proliferative forstyrrelser
US20030138405A1 (en) * 2001-04-17 2003-07-24 Juan Fueyo Conditionally replicative adenovirus to target the Rb and Rb-related pathways

Also Published As

Publication number Publication date
TW201005097A (en) 2010-02-01
ATE555388T1 (de) 2012-05-15
CN1666105A (zh) 2005-09-07
EP1520175B1 (en) 2007-11-07
EP1890151B1 (en) 2012-04-25
DK1890151T3 (da) 2012-06-18
EP1520175A2 (en) 2005-04-06
AR039768A1 (es) 2005-03-09
WO2004003562A2 (en) 2004-01-08
CN1666105B (zh) 2015-11-25
JP2005531306A (ja) 2005-10-20
BR0311983A (pt) 2005-04-26
CA2487824A1 (en) 2004-01-08
IL220139A (en) 2013-03-24
WO2004003562A3 (en) 2004-05-06
DK1520175T3 (da) 2008-02-11
IL165498A0 (en) 2006-01-15
TW200401032A (en) 2004-01-16
HK1069877A1 (en) 2005-06-03
IL220139A0 (en) 2012-07-31
DE60317331D1 (de) 2007-12-20
ES2292981T3 (es) 2008-03-16
NZ537116A (en) 2008-04-30
ATE377754T1 (de) 2007-11-15
MXPA04012414A (es) 2005-04-19
EP1890151A1 (en) 2008-02-20
AU2008207579A1 (en) 2008-09-18
US7306902B2 (en) 2007-12-11
PT1890151E (pt) 2012-05-25
US8222036B2 (en) 2012-07-17
CA2487824C (en) 2013-08-20
US20080014577A1 (en) 2008-01-17
TWI402345B (zh) 2013-07-21
HK1112509A1 (en) 2008-09-05
ES2385845T3 (es) 2012-08-01
TWI327167B (en) 2010-07-11
US20040029112A1 (en) 2004-02-12
DE60317331T2 (de) 2008-08-21
AU2003245760A1 (en) 2004-01-19
SI1890151T1 (sl) 2012-08-31
US20100105122A1 (en) 2010-04-29
AU2008207579B2 (en) 2011-10-20
AU2003245760B2 (en) 2008-07-03
TWI334444B (en) 2010-12-11

Similar Documents

Publication Publication Date Title
TW200940709A (en) Oncolytic viruses as phenotyping agents for neoplasms
AU2002366641A1 (en) Methods for inhibiting ocular processes
BRPI0607753A2 (pt) método para prever um efeito clìnico em resposta a um tratamento de uma leucemia; método para prever um efeito clìnico de uma leucemia; método para selecionar um tratamento para um paciente com leucemia; método para o diagnóstico ou monitoramento de ocorrência, desenvolvimento, progressão ou tratamento de uma leucemia; arranjo para uso num método para prever um efeito clìnico para um paciente aml; arranjo para uso num método de diagnóstico de aml; meio legìvel por computador; kit para o prognóstico de aml
ATE424560T1 (de) Marker für neuromyelitis optica
TW200707614A (en) Testing method detecting localized failure on a semiconductor wafer
DE69931892D1 (de) Test für antibiotikaresistenz
DE602007011566D1 (en) Ankheit
WO2005079332A3 (en) Display enhanced testing for concussions and mild traumatic brain injury
WO2005118878A3 (en) Methods of screening for cell proliferation or neoplastic disorders
DK0939651T3 (da) Materialer og metoder ved diagnose og behandling af præeclapsia
HK1143406A1 (zh) 促認知藥的篩選方法
DK1075277T4 (da) Fremgangsmåder til detektion og inhibering af angiogenese
WO2007134028A3 (en) Biomarkers for depression and methods using the same
WO2002000933A3 (en) Screening assays for identifying modulators of the inflammatory or immune responses
WO2006110748A3 (en) Response gene to complement 32 (rgc-32) in disease
BRPI0519060A2 (pt) kit de teste rÁpido para a detecÇço e a localizaÇço de élceras nos eqÜinos e seu mÉtodo de produÇço
DE60043775D1 (de) Verfahren zum identifizieren von präneoplastischen und neoplastischen stadien in säugern
Seager et al. Effects of short‐term oxygen depletion on fish
Seisdedo et al. Analysis of tools for trophic status assessment of water in Cienfuegos bay, Cuba
WO2006133027A3 (en) Methods for immobilizing molecules on surfaces
DE502005011186D1 (de) Stabiles, chromogenes Testreagenz und dessen Verwendung in gerinnungsdiagnostischen Tests
AU2003293556A1 (en) Methods of diagnosing and treating cancer
Black Language dysfluency in the deaf inpatient population
MX2021009281A (es) Metodos de deteccion de legionella.
RU2005108805A (ru) Способ диагностики синдрома системной воспалительной реакции по основным системам жизнеобеспечения

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent